GlassScriptPhysician profile
Cody Ernst
NPI 1386235463
$2,548.36
in general payments reported to CMS, 2019-2025
20 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $842 · 2022: $144 · 2023: $99.93 · 2024: $864 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.25 | 2021-2025 | |
| Axsome Therapeutics, INC. | $332.55 | 2024-2025 | Auvelity |
| Lundbeck LLC | $294.59 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $237.08 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $223.03 | 2021-2025 | Trintellix |
| Alkermes, INC. | $222.83 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $193.19 | 2021-2025 | Rexulti |
| Janssen Biotech, INC. | $130.01 | 2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $121.87 | 2022 | |
| Vanda Pharmaceuticals INC. | $66.74 | 2021-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.05 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $52.60 | 2021 | |
| Avanir Pharmaceuticals, INC. | $39.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.66 | 2021-2024 | Spravato |
| Indivior INC. | $28.09 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $26.67 | 2024 | Subvenite |
| Noven Therapeutics, LLC | $23.72 | 2021 | |
| Vertical Pharmaceuticals, LLC | $20.53 | 2025 | Relexxii |
| Noven Pharmaceuticals, INC. | $17.76 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Ernst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.